These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 24970800)

  • 1. Tumor-derived CXCL8 signaling augments stroma-derived CCL2-promoted proliferation and CXCL12-mediated invasion of PTEN-deficient prostate cancer cells.
    Maxwell PJ; Neisen J; Messenger J; Waugh DJ
    Oncotarget; 2014 Jul; 5(13):4895-908. PubMed ID: 24970800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potentiation of inflammatory CXCL8 signalling sustains cell survival in PTEN-deficient prostate carcinoma.
    Maxwell PJ; Coulter J; Walker SM; McKechnie M; Neisen J; McCabe N; Kennedy RD; Salto-Tellez M; Albanese C; Waugh DJ
    Eur Urol; 2013 Aug; 64(2):177-88. PubMed ID: 22939387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Towards in situ tissue repair: human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 and CCR2, and migrate upon stimulation with CXCL8 but not CCL2.
    Ringe J; Strassburg S; Neumann K; Endres M; Notter M; Burmester GR; Kaps C; Sittinger M
    J Cell Biochem; 2007 May; 101(1):135-46. PubMed ID: 17295203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CXCL8/IL-8 and CXCL12/SDF-1alpha co-operatively promote invasiveness and angiogenesis in pancreatic cancer.
    Matsuo Y; Ochi N; Sawai H; Yasuda A; Takahashi H; Funahashi H; Takeyama H; Tong Z; Guha S
    Int J Cancer; 2009 Feb; 124(4):853-61. PubMed ID: 19035451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Constitutive and treatment-induced CXCL8-signalling selectively modulates the efficacy of anti-metabolite therapeutics in metastatic prostate cancer.
    Wilson C; Maxwell PJ; Longley DB; Wilson RH; Johnston PG; Waugh DJ
    PLoS One; 2012; 7(5):e36545. PubMed ID: 22590561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergy between coproduced CC and CXC chemokines in monocyte chemotaxis through receptor-mediated events.
    Gouwy M; Struyf S; Noppen S; Schutyser E; Springael JY; Parmentier M; Proost P; Van Damme J
    Mol Pharmacol; 2008 Aug; 74(2):485-95. PubMed ID: 18469140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling.
    Conley-LaComb MK; Saliganan A; Kandagatla P; Chen YQ; Cher ML; Chinni SR
    Mol Cancer; 2013 Jul; 12(1):85. PubMed ID: 23902739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibroblast-derived CXCL12 regulates PTEN expression and is associated with the proliferation and invasion of colon cancer cells via PI3k/Akt signaling.
    Ma J; Sun X; Wang Y; Chen B; Qian L; Wang Y
    Cell Commun Signal; 2019 Sep; 17(1):119. PubMed ID: 31500630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen receptor and chemokine receptors 4 and 7 form a signaling axis to regulate CXCL12-dependent cellular motility.
    Hsiao JJ; Ng BH; Smits MM; Wang J; Jasavala RJ; Martinez HD; Lee J; Alston JJ; Misonou H; Trimmer JS; Wright ME
    BMC Cancer; 2015 Mar; 15():204. PubMed ID: 25884570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-faceted roles for CXC-chemokines in prostate cancer progression.
    Waugh DJ; Wilson C; Seaton A; Maxwell PJ
    Front Biosci; 2008 May; 13():4595-604. PubMed ID: 18508531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SLUG promotes prostate cancer cell migration and invasion via CXCR4/CXCL12 axis.
    Uygur B; Wu WS
    Mol Cancer; 2011 Nov; 10():139. PubMed ID: 22074556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An updated review on the role of the CXCL8-CXCR1/2 axis in the progression and metastasis of breast cancer.
    Mishra A; Suman KH; Nair N; Majeed J; Tripathi V
    Mol Biol Rep; 2021 Sep; 48(9):6551-6561. PubMed ID: 34426905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AMD3100 inhibits epithelial-mesenchymal transition, cell invasion, and metastasis in the liver and the lung through blocking the SDF-1α/CXCR4 signaling pathway in prostate cancer.
    Zhu WB; Zhao ZF; Zhou X
    J Cell Physiol; 2019 Jul; 234(7):11746-11759. PubMed ID: 30537000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of androgen receptor signaling in prostate cancer-associated fibroblasts (CAFs) promotes CCL2- and CXCL8-mediated cancer cell migration.
    Cioni B; Nevedomskaya E; Melis MHM; van Burgsteden J; Stelloo S; Hodel E; Spinozzi D; de Jong J; van der Poel H; de Boer JP; Wessels LFA; Zwart W; Bergman AM
    Mol Oncol; 2018 Aug; 12(8):1308-1323. PubMed ID: 29808619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIF-1 and NF-kappaB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells.
    Maxwell PJ; Gallagher R; Seaton A; Wilson C; Scullin P; Pettigrew J; Stratford IJ; Williams KJ; Johnston PG; Waugh DJ
    Oncogene; 2007 Nov; 26(52):7333-45. PubMed ID: 17533374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional activity of CXCL8 receptors, CXCR1 and CXCR2, on human malignant melanoma progression.
    Gabellini C; Trisciuoglio D; Desideri M; Candiloro A; Ragazzoni Y; Orlandi A; Zupi G; Del Bufalo D
    Eur J Cancer; 2009 Sep; 45(14):2618-27. PubMed ID: 19683430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion.
    Singh S; Singh UP; Grizzle WE; Lillard JW
    Lab Invest; 2004 Dec; 84(12):1666-76. PubMed ID: 15467730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PTEN deficiency promotes macrophage infiltration and hypersensitivity of prostate cancer to IAP antagonist/radiation combination therapy.
    Armstrong CW; Maxwell PJ; Ong CW; Redmond KM; McCann C; Neisen J; Ward GA; Chessari G; Johnson C; Crawford NT; LaBonte MJ; Prise KM; Robson T; Salto-Tellez M; Longley DB; Waugh DJ
    Oncotarget; 2016 Feb; 7(7):7885-98. PubMed ID: 26799286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. G31P, an antagonist against CXC chemokine receptors 1 and 2, inhibits growth of human prostate cancer cells in nude mice.
    Liu X; Peng J; Sun W; Yang S; Deng G; Li F; Cheng JW; Gordon JR
    Tohoku J Exp Med; 2012 Oct; 228(2):147-56. PubMed ID: 23019013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The CXCL8-CXCR1/2 pathways in cancer.
    Liu Q; Li A; Tian Y; Wu JD; Liu Y; Li T; Chen Y; Han X; Wu K
    Cytokine Growth Factor Rev; 2016 Oct; 31():61-71. PubMed ID: 27578214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.